Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 2
2020 pubmed 3 citations

Chronic ghrelin administration suppresses IKK/NF-κB/BACE1 mediated Aβ production in primary neurons and improves cognitive function via upregulation of PP1 in STZ-diabetic rats.

Ma. Lou-Yan LY; Liu. Song-Fang SF; Du. Jun-Hui JH; Niu. Yu Y; Hou. Peng-Fei PF; Shu. Qing Q; Ma. Ran-Ran RR; Wu. Song-Di SD; Qu. Qiu-Min QM; Lv. Ya-Li YL

Key Findings

  • Chronic ghrelin administration improved memory performance in STZ‑diabetic rats.
  • Ghrelin reduced activation of the IKK/NF‑κB/BACE1 pathway and lowered amyloid‑beta levels in the hippocampus.
  • The cognitive benefits were linked to increased expression of protein phosphatase 1 (PP1) and were blocked by the GHSR antagonist (D‑lys3)‑GHRP‑6.

Practical Outcomes

  • The study suggests that boosting ghrelin signaling might protect brain health in metabolic disease, but the experiments used direct brain injections in rats, which isn’t a feasible human protocol. For biohackers, the findings hint that ghrelin‑related peptides could have neuro‑protective potential, yet more human‑focused research is needed before any dosing or supplementation advice can be made.

Summary

In diabetic rats, giving the hormone ghrelin helped them think better and reduced brain proteins linked to Alzheimer's. It worked by turning up a brain enzyme called PP1 and shutting down a stress pathway (IKK/NF‑κB/BACE1) that makes harmful amyloid‑beta. When the researchers blocked ghrelin with a compound called (D‑lys3)‑GHRP‑6, the benefits disappeared.

Abstract

Diabetic rats display cognition impairments accompanied by activation of NF-κB signalling and increased Aβ expression. Ghrelin has been suggested to improve cognition in diabetic rats. In this study, we investigated the role of ghrelin on cognition and NF-κB mediated Aβ production in diabetic rats. A diabetic rat model was established with streptozotocin (STZ) injection, and diabetic rats were intracerebroventricularly administered with ghrelin or (D-lys3)-GHRP-6 (DG). Our results showed that diabetic rats had cognition impairment in the Morris water maze test, accompanied by the higher expression of Aβ in the hippocampus. Western blot analysis showed that diabetic rats exhibited significantly decreased levels of GHSR-1a and protein phosphatase 1 (PP1) in the hippocampus and increased activation of the IKK/NF-κB/BACE1 pathway. Chronic ghrelin administration upregulated hippocampal PP1 expression, suppressed IKK/NF-κB/BACE1 mediated Aβ production, and improved cognition in STZ-induced diabetic rats. These effects were reversed by DG. Then, primary rat hippocampal neurons were isolated and treated with high glucose, followed by Ghrelin and DG, PP1 or IKK. Similar to the in vivo results, high glucose suppressed the expression levels of GHSR-1a and PP1, activated the IKK/NF-κB/BACE1 pathway, increased Aβ production. Ghrelin suppressed IKK/NF-κB/BACE1 induced Aβ production. This improvement was reversed by DG and a PP1 antagonist and was enhanced by the IKK antagonist. Our findings indicated that chronic ghrelin administration can suppress IKK/NF-κB/BACE1 mediated Aβ production in primary neurons with high glucose treatment and improve the cognition via PP1 upregulation in diabetic rats.

Study Information

Provider

pubmed

Year

2020

Date

2020-01-02T00:00:00.000Z

DOI

10.1016/j.nlm.2019.107155

Citations

3

References

52